Search results for " ASC"

showing 10 items of 168 documents

Inducible lectins with galectin properties and human IL1alpha epitopes opsonize yeast during the inflammatory response of the ascidian Ciona intestin…

2007

Studies on inducible ascidian lectins may shed light on the evolutionary emergence of cytokine functions. Here, we show that the levels of opsonins, with IL1alpha-epitopes, increase in Ciona intestinalis hemolymph as a response to an inflammatory stimulus and, in particular, to intratunic injection of lipopolysaccharide (LPS). The inflammatory agent promptly (within 4 h) enhances Ca(2+)-independent serum hemagglutinating and opsonizing activities, which are both inhibited by D-galactose and D-galactosides (alpha-lactose, N-acetyl-D-lactosamine, thio-digalactoside), suggesting that anti-rabbit erythrocyte lectins with galectin properties are involved as opsonins. Inducible galectin molecules…

LipopolysaccharidesHistologyLipopolysaccharideGalectinsSaccharomyces cerevisiaeCross ReactionsEpitopeEvolution . Inflammatory response . Phagocytosis . Opsonins . Lectins . IL1α-like galectins . Ascidian Ciona intestinalis (Tunicata)AntibodiesPathology and Forensic Medicinelaw.inventionchemistry.chemical_compoundEpitopesWestern blotPhagocytosisOpsonin ProteinslawHemolymphInterleukin-1alphaLectinsmedicineAnimalsHumansCiona intestinalisGalectinbiologymedicine.diagnostic_testGalactoseGalactosidesCell BiologyBlood ProteinsOpsonin Proteinsbiology.organism_classificationMolecular biologyBlood proteinsRecombinant ProteinsCiona intestinalisHemagglutininsBiochemistrychemistryRecombinant DNACalciumRabbitsCell and tissue research
researchProduct

Inflamed adult pharynx tissues and swimming larva of Ciona intestinalis share CiTNFalpha-producing cells.

2010

In situ hybridisation and immunohistochemistry analyses have shown that the Ciona intestinalis tumour necrosis factor alpha gene (CiTNFalpha), which has been previously cloned and sequenced, is expressed either during the inflammatory pharynx response to lipopolysaccharide (LPS) or during the swimming larval phase of development. Granulocytes with large granules and compartment/morula cells are CiTNFalpha-producing cells in both inflamed pharynx and larvae. Pharynx vessel endothelium also takes part in the inflammatory response. Haemocyte nodules in the vessel lumen or associated with the endothelium suggest the involvement of CiTNFalpha in recruiting lymphocyte-like cells and promoting the…

LipopolysaccharidesPathologymedicine.medical_specialtyHistologyHemocytesEndotheliumEvolutionMesenchymeSettore BIO/05 - ZoologiaInflammationIn situ hybridizationBiologyAscidia Ciona intestinalisPathology and Forensic MedicinemedicineAnimalsCiona intestinalisTumour necrosis factor; Pharynx; Inflammation; Haemocytes; Larval development; Innate immunity; Evolution; Ascidia Ciona intestinalisIn Situ Hybridization FluorescencePhylogenyInflammationInnate immunityInnate immune systemTumor Necrosis Factor-alphaPharynxMetamorphosis BiologicalHaemocytePharyngitisCell Biologybiology.organism_classificationImmunohistochemistryCiona intestinalismedicine.anatomical_structureLarval developmentLarvaImmunohistochemistryPharynxmedicine.symptomTumour necrosis factorGranulocytesCell and tissue research
researchProduct

CiC3-1a-Mediated Chemotaxis in the Deuterostome Invertebrate Ciona intestinalis (Urochordata)

2003

Abstract Deuterostome invertebrates possess complement genes, and in limited instances complement-mediated functions have been reported in these organisms. However, the organization of the complement pathway(s), as well as the functions exerted by the cloned gene products, are largely unknown. To address the issue of the presence of an inflammatory pathway in ascidians, we expressed in Escherichia coli the fragment of Ciona intestinalis C3-1 corresponding to mammalian complement C3a (rCiC3-1a) and assessed its chemotactic activity on C. intestinalis hemocytes. We found that the migration of C. intestinalis hemocytes toward rCiC3-1a was dose dependent, peaking at 500 nM, and was specific for…

Lipopolysaccharidescomplement system ascidiansHemocytesMolecular Sequence DataIn situ hybridizationPertussis toxinimmunologyHemolymphEscherichia coliAnimalsImmunology and AllergyCiona intestinalisAmino Acid SequencePeptide sequenceinnate immunityInflammationCell-Free SystemChemotactic FactorsbiologyImmune SeraRiboprobeChemotaxisAnatomybiology.organism_classificationRecombinant ProteinsComplement systemCell biologyCiona intestinalisChemotaxis LeukocyteHemocyte migrationPertussis ToxinCell Migration InhibitionComplement C3a
researchProduct

New clinical and pathophysiological perspectives defining the trajectory of cirrhosis

2021

Traditionally, the complications of cirrhosis, namely variceal bleeding, ascites and hepatic encephalopathy, were thought to result predominantly from circulatory dysfunction and altered organ perfusion arising as a result of portal hypertension. Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts…

Liver Cirrhosis0301 basic medicinemedicine.medical_specialtyVaricesCirrhosisSystemic inflammationImmune System Phenomena03 medical and health sciences0302 clinical medicineImmunopathologyAscitesmedicineAcute on chronic liver failureHumansDecompensationIntensive care medicineHepatic encephalopathyHepatic encephalopathyInflammationHepatologybusiness.industryResearchOrgan dysfunctionGastroenterologyAscitesAcute on chronic liver failure; Ascites; Cirrhosis; Hepatic encephalopathy; Infection; Inflammation; Varicesmedicine.disease030104 developmental biologyCirrhosisDisease ProgressionPortal hypertension030211 gastroenterology & hepatologymedicine.symptombusinessInfection
researchProduct

Immune-inflammatory and metabolic effects of high dose furosemide plus hypertonic saline solution (HSS) treatment in cirrhotic subjects with refracto…

2016

Introduction Patients with chronic liver diseases are usually thin as a result of hypermetabolism and malnutrition expressed by reduced levels of leptin and impairment of other adyponectins such as visfatin. Aims We evaluated the metabolic and inflammatory effects of intravenous high-dose furosemide plus hypertonic saline solutions (HSS) compared with repeated paracentesis and a standard oral diuretic schedule, in patients with cirrhosis and refractory ascites. Methods 59 consecutive cirrhotic patients with refractory ascites unresponsive to outpatient treatment. Enrolled subjects were randomized to treatment with intravenous infusion of furosemide (125-250mg⁄bid) plus small volumes of HSS …

Liver CirrhosisMaleLeptinCirrhosisPhysiologyPeptide Hormonesmedicine.medical_treatmentdiureticlcsh:MedicineVisfatinPathology and Laboratory MedicineFurosemide; Hypertonic Saline Solution; TNF-alpha; IL-1beta; IL-6; ANP; BNP; Visfatin; Leptin; cirrhosis; refractory ascites; paracentesis; diureticBiochemistryGastroenterology0302 clinical medicineRecurrenceFurosemideImmune PhysiologyMedicine and Health SciencesParacentesisDiureticslcsh:ScienceImmune ResponseSalineHypertonicInnate Immune SystemMultidisciplinarymedicine.diagnostic_testLiver DiseasesPhysicsLeptinrefractory asciteAscitesClassical MechanicsFurosemideHematologyMiddle AgedBody FluidsBloodTreatment OutcomeCirrhosis030220 oncology & carcinogenesisPhysical SciencesHypermetabolismCytokinesAdministration IntravenousFemale030211 gastroenterology & hepatologyAnatomyInflammation MediatorsANPResearch ArticleTNF-alphamedicine.drugparacentesimedicine.medical_specialtyInflammatory DiseasesImmunologyGastroenterology and HepatologyBlood Plasma03 medical and health sciencesSigns and SymptomsDiagnostic MedicineOsmotic PressureInternal medicinePressuremedicineTonicityHumansAgedInflammationSaline Solution HypertonicIL-6business.industrylcsh:RBiology and Life SciencesMolecular DevelopmentIL-1betamedicine.diseaseHormonesHypertonic salineEndocrinologyImmune Systemlcsh:QHypertonic Saline SolutionDiureticbusinessBiomarkersDevelopmental BiologyBNPcirrhosi
researchProduct

Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

2018

Background Evidence is scarce on the efficacy of long-term human albumin (HA) administration in patients with decompensated cirrhosis. The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study was designed to clarify this issue. Methods We did an investigator-initiated multicentre randomised, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. We randomly assigned patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly…

Liver CirrhosisMaleTime FactorsCirrhosisKaplan-Meier Estimatelaw.inventionascites0302 clinical medicineHepatorenal syndromeRandomized controlled trialFurosemidelawAscitesClinical endpointParacentesisDiureticsalbumin decompensated cirrhosiMineralocorticoid Receptor AntagonistsSettore MED/12 - GastroenterologiaMedicine (all)Hazard ratioGeneral MedicineMiddle AgedSurvival RateCirrhosis030220 oncology & carcinogenesisDrug Therapy CombinationFemale030211 gastroenterology & hepatologyQuality-Adjusted Life Yearsmedicine.symptomHyponatremiamedicine.medical_specialty03 medical and health sciencesAlbuminsInternal medicinemedicineHumansSurvival ratealbuminAgedbusiness.industrycirrhosis; albumin; ascitesmedicine.diseaseClinical trialalbumin cirrhosis ascites liver decompensationQuality of LifeHyperkalemiabusinessEsophagus Varices Portal Hypertension Varicosis
researchProduct

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid

2022

Background & Aims Obeticholic acid (OCA) has recently been restricted in patients with primary biliary cholangitis (PBC) with "advanced cirrhosis" because of its narrow therapeutic index. We aimed to better define the predicting factors of hepatic serious adverse events (SAEs) and non-response in cirrhotic patients undergoing OCA therapy. Methods Safety and efficacy of treatment were evaluated in a cohort of consecutive PBC cirrhotic patients started with OCA. OCA response was evaluated according to the Poise criteria. Risk factors for hepatic SAEs and non-response were reported as risk ratios (RR) with 95% confidence intervals (CIs). Results One hundred PBC cirrhotics were included, 97…

Liver CirrhosisMaleliver decompensationsafetyHepatologyLiver Cirrhosis Biliarydecision curve analysis; efficacy; liver decompensation; safety; total bilirubin; Albumins; Ascites; Bilirubin; Chenodeoxycholic Acid; Humans; Liver Cirrhosis; Male; Liver Cirrhosis BiliaryBiliaryefficacyAscitesBilirubinChenodeoxycholic Acidtotal bilirubindecision curve analysiSettore MED/12AlbuminsHumansdecision curve analysis
researchProduct

Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites: A Meta-analysis of Individual Patient Data

2007

Several randomized controlled trials have compared a transjugular intrahepatic portosystemic shunt (TIPS) with large-volume paracentesis in cirrhotic patients with refractory ascites. Although all agree that TIPS reduces the recurrence rate of ascites, survival is controversial. The aim of this study was to compare the effects of TIPS and large-volume paracentesis in cirrhotic patients with refractory ascites by means of meta-analysis of individual patient data from 4 randomized controlled trials.The study population consisted of 305 patients: 149 allocated to TIPS and 156 to paracentesis. Cumulative probabilities of transplant-free survival and of hepatic encephalopathy (HE) were estimated…

Liver CirrhosisMalemedicine.medical_specialtymedicine.medical_treatmentKaplan-Meier EstimateGastroenterologySpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseHepatorenal syndromeRisk FactorsInternal medicineAscitesmedicineParacentesisHumansParacentesisHepatic encephalopathyAgedFirst episodeHepatologymedicine.diagnostic_testbusiness.industrySodiumGastroenterologyAscitesBilirubinPatient dataMiddle Agedmedicine.diseaseLiver TransplantationSurgeryTreatment OutcomeMeta-analysisHepatic EncephalopathyRegression AnalysisFemaleRefractory ascitesPortasystemic Shunt Transjugular Intrahepaticmedicine.symptombusinessTransjugular intrahepatic portosystemic shuntGastroenterology
researchProduct

Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (…

2021

Abstract Portal hypertension and ascites are two crucial events in the natural history of liver cirrhosis, whose appearance marks a downward shift in the prognosis of the disease. Over the years, several international and national societies have issued clinical practice guidelines for the diagnosis and management of portal hypertension and ascites. The present document addresses the needs of an updated guidance on the clinical management of these conditions. Accordingly, the AISF Governing Board appointed a multi-disciplinary committee of experts for drafting an update of the most recent EASL Clinical Practice Guidelines. The aim of this work was to adapt the EASL recommendations to nationa…

Liver CirrhosisPopulationScopusDiseaseEsophageal varicesAscitesHypertension PortalMedicineHumanseducationPortal hypertensioneducation.field_of_studyVariceal bleedingHepatologyEsophageal varicebusiness.industryGastroenterologyAscitesmedicine.diseaseAcute kidney injuryClinical PracticeNatural historyVariceal bleeding.ItalyAcute kidney injury; Ascites; Esophageal varices; Hepatorenal syndrome; Portal hypertension; Variceal bleeding; Ascites; Humans; Hypertension Portal; Italy; Liver CirrhosisHypertensionAscitePortal hypertensionHepatorenal syndromePortalMedical emergencymedicine.symptombusinessResource utilizationHuman
researchProduct

Deregulation of Notch1 pathway and circulating endothelial progenitor cell (EPC) number in patients with bicuspid aortic valve with and without ascen…

2018

AbstractBicuspid aortic valve (BAV) is frequently associated with the development of ascending aortic aneurysm, even if the underlying mechanisms remain to be clarified. Here, we investigated if a deregulation of Notch1 signaling pathway and endothelial progenitor cells (EPCs) number is associated with BAV disease and an early ascending aortic aneurysm (AAA) onset. For this purpose, 70 subjects with BAV (M/F 50/20; mean age: 58.8 ± 14.8 years) and 70 subjects with tricuspid aortic valve (TAV) (M/F 35/35; mean age: 69.1 ± 12.8 years) and AAA complicated or not, were included. Interestingly, patients with AAA showed a significant increase in circulating Notch1 levels and EPC number than subje…

Male0301 basic medicineAortic valveNotch1 signaling pathwatHeart Valve Diseases030204 cardiovascular system & hematologyAortic aneurysm0302 clinical medicineBicuspid aortic valveBicuspid Aortic Valve DiseaseNotch Signaling Pathwaycirculating EPC populationsReceptor Notch1ReceptorAortaEndothelial Progenitor CellsAged 80 and overMultidisciplinaryQRMiddle AgedAortic Aneurysmmedicine.anatomical_structureAortic Valvecardiovascular systemCardiologyMedicineFemaleTricuspid ValveSignal TransductionAdultmedicine.medical_specialtyBicuspid aortic valveEndothelial Progenitor Cells (EPC)ScienceNotch signaling pathwayBicuspid Aortic Valve (BAV)Endothelial progenitor cellArticleBicuspid aortic valve; Notch1 signaling pathwat; ascending aortic aneurysm03 medical and health sciencesascending aortic aneurysmInternal medicinemedicineHumansIn patientcardiovascular diseasesProgenitor cellNotch 1 signaling pathwayAgedTricuspid Aortic Valve (TAV)Ascending Aorta Aneurysm (AAA)business.industrySettore MED/23 - Chirurgia Cardiacamedicine.disease030104 developmental biologybusiness
researchProduct